AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 304 min read$PEN

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of

Original reporting
SEC EDGAR 8-K
Published Jul 30, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PEN
Bullish
high confidence
Mentioned
$PEN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PENBullishMed
01

Why it matters

Traders can update near-term expectations using the reported Q2 growth and margin, while also adjusting for the absence of full-year 2026 guidance due to the acquisition process.

02

Market read

Q2 financials support an improving operating profile, but the acquisition removes full-year guidance, increasing reliance on deal progress and regulatory risk.

03

What to watch

Net income fell vs prior-year quarter ($34.8M vs $45.3M) and the company highlighted risks that regulatory approvals may not be obtained, which can dominate near-term trading.

Relevance 7/10Novelty 6/10Timing: filed after market close, July 30, 2026

Background

Penumbra filed an 8-K with Q2 2026 results and noted it is pending acquisition by Boston Scientific (BSX).

Company-level read

Ticker impact

$PENBullishHigh confidence
Context

Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY) and disclosed it will not provide full-year 2026 guidance due to the pending BSX acquisition.

Expected impact

Near-term sentiment likely positive on growth and margin, but guidance absence and deal-close risk can cap upside and increase volatility.

Evidence & confidence

The filing provides concrete quarterly financials (revenue, margins, operating income) and a specific forward-looking change (no full-year guidance) tied to the pending Boston Scientific acquisition.

Market effects

Sector

Thrombectomy device peers may see read-across on procedure demand and pricing/margin durability, but deal pendency reduces forward visibility for Penumbra specifically.

Regional

No explicit regional macro drivers beyond disclosed US vs international revenue growth rates.

Global

Limited broader market impact; primarily company-specific and acquisition-related.

Counterpoint

What could challenge this read

The strong Q2 growth and margin could be partially offset by acquisition-related expense drag and uncertainty around deal timing, making the stock more sensitive to BSX deal headlines than fundamentals.

Key entities

  • company
    Penumbra, Inc.

    NYSE-listed thrombectomy company reporting Q2 2026 results and acquisition-related guidance change.

  • company
    Boston Scientific Corporation

    Buyer in the pending acquisition referenced as the reason Penumbra will not provide full-year 2026 guidance.

Read at source← All news

Related articles

OCT 22
$PENHighAI 9/10

Deep Vein Thrombosis (DVT)

Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.

dicardiology.com1 min
OCT 20
$PENHighAI 9/10

FDA clears Penumbra’s CAVT technology for DVT treatment

Penumbra Inc. (PEN) received FDA clearance for its Lightning CAVT technology to treat deep vein thrombosis, supported by positive BOLT-DVT trial results. The trial showed 98% of patients had complete or near-complete clot removal with a low adverse event rate. Penumbra's technology uses advanced algorithms for clot detection and removal.

investing.com2 min
OCT 20
$PENHighAI 8/10

98% of patients had all or nearly all of their clot removed in a trial. FDA cleared the device to treat deep-vein clots.

Penumbra's CAVT technology received FDA clearance for treating deep-vein thrombosis (DVT). The BOLT-DVT trial showed 98% of patients had successful clot removal, with immediate pain relief and improved quality of life. No serious device-related adverse events were reported. Penumbra's Lightning Flash technology aims to enhance clot removal safety and efficiency.

stocktitan.net2 min
AUG 21
$BSXHighAI 8/10

Boston Scientific Climbs 2% After Steep Decline, Regains 38% of Thursday’s Loss

Boston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).

ts2.tech2 min
AUG 20
$PENMed

Panoro Energy to Acquire Côte

Panoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.

euro-petrole.com2 min